ABL1 and coronary artery disorder: In symptomatic patients (stable angina, limiting dyspnea) with clinical suspicion of coronary artery disease (CAD), functional imaging testing is recommended, especially before the use of anticancer therapies associated with vascular toxicity (e.g., fluoropyrimidines, VEGFi, breakpoint cluster region–Abelson oncogene locus (BCR-ABL), tyrosine kinase inhibitors (TKIs)).